香连丸治疗溃疡性结肠炎的临床及分子机制研究进展
打开文本图片集
中图分类号R965；R969；R975 文献标志码A 文章编号 1001-0408（2025）20-2609-06
DOI 10.6039/j.issn.1001-0408.2025.20.22
Research progress on clinical and molecular mechanisms of Xianglian pils in the treatment of ulcerative colitis
LI Ying'，ZHANG Zaoyu'，DENGRong，CHEN Jiale'，LI Yanlong²（1.Schoolof Integrated Traditional Chinese and Western Medicine，Gansu University of Chinese Medicine，Lanzhou 730o， China;2.Spleen and Stomach DiseaseDiagnosis and Treatment Center，Gansu Provincial Hospital of Traditional Chinese Medicine，Lanzhou 730050，China）
ABSTRACTUlcerativecolitis（UC）isachronicintestinalautoimmunedisease，withclinicalmanifestations includingabdomial pain，diarrea，mucusandbloodystols，anditspathogenesis iscomplex.Theclassic presription Xianglianpills（XL）hasben widelyusedintheclinicaltreatmentofUCinrecentyears.Ithasfewadversereactions，goodpatienttolerance，and shows significantpotentialforclinicalaplication.However，thereiscurrentlynocomprehensiveintegrationofevidenceonitsclinical research and molecular mechanisms.Through a systematicreviewof theclinical researchand molecular mechanisms of XLP inthe treatmentofUC，itisfoundthat XLPanditsmodifiedformulas，whenusedincombination withchemicaldrugs，cansignificantly improvetesymptomsofUCpatientsandreduceintestinalinflammation，withsuperioreficacycomparedtochemicaldrugsalone. Itsmechanismofactioninvolvesregulating pan-apoptosis，immuneresponse，signalingpathways（hypoxia-induciblefactor ∇⋅l∝ ， nuclear factor- κB ，etc.），intestinal flora，andrepairing the intestinal mucosalbarrier.Its medicinal materials，monomersandactive componentscanalsopreventthediferentiationofhelperTcells17andrestore thebalanceofM1/M2cellsthroughregulating multiple pathways such as Wnt/β -catenin and Janus kinase/signal transducer and activator of transcription， thereby reducing intestinal damage in UC.
KEYWORDSXianglian pills；ulcerative colitis；clinical research；molecular mechanism；research progress
溃疡性结肠炎（ulcerativecolitis，UC）是炎症性肠病的主要类型之一，是一种局限于黏膜及黏膜下层的慢性肠道自身免疫性疾病，以腹痛、腹泻、黏液便和血便等为常见症状。（剩余12817字）
